infectious diseases

Pfizer, Gilead, GSK to Capture Growing Infectious Diseases Market as J&J Pulls Back
Pfizer, Gilead, GSK to Capture Growing Infectious Diseases Market as J&J Pulls Back
BioSpace
infectious diseases
Pfizer
Gilead Sciences
GSK
JNJ
Flag link:
Carver Bio Plants Seed to Treat Viral Threats with CRISPR Cas13
Carver Bio Plants Seed to Treat Viral Threats with CRISPR Cas13
BioSpace
Carver Bio
CRISPR
funding
infectious diseases
RNA
gene therapy
Flag link:
Where’s the demand in human challenge clinical trials?
Where’s the demand in human challenge clinical trials?
Clinical Trials Arena
clinical trials
COVID-19
infectious diseases
Flag link:
Sanofi culls early infectious disease, blood disorder asset as it ramps up phase 3 for also-ran COVID vax
Sanofi culls early infectious disease, blood disorder asset as it ramps up phase 3 for also-ran COVID vax
Fierce Biotech
Sanofi
infectious diseases
sutimlimab
Flag link:
Pfizer buys Amplyx to grow infectious disease pipeline
Pfizer buys Amplyx to grow infectious disease pipeline
Fierce Biotech
Pfizer
M&A
Amplyx
infectious diseases
Flag link:
Biotech startup Repertoire adds $189M to expand array of immune medicines
Biotech startup Repertoire adds $189M to expand array of immune medicines
MedCity News
Repertoire Immune Medicines
autoimmune disease
infectious diseases
Flag link:
Pharmaceutical giants not ready for next pandemic, report warns
Pharmaceutical giants not ready for next pandemic, report warns
The Guardian, UK
WHO
infectious diseases
Public Health
pandemic
Flag link:
Moderna to run three new infectious disease vaccine development programs, EU vaccine distribution begins
Moderna to run three new infectious disease vaccine development programs, EU vaccine distribution begins
Biopharma Reporter
Moderna Therapeutics
vaccines
infectious diseases
Flag link:
2021 forecast: COVID-19 brings infectious disease R&D out of the wilderness
2021 forecast: COVID-19 brings infectious disease R&D out of the wilderness
Fierce Biotech
infectious diseases
R&D
COVID-19
Flag link:
Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work
Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work
Endpoints
Vir Biotechnology
Harbor BioMed
cancer
infectious diseases
Flag link:
Here’s how Covid-19 has affected funding, development in infectious diseases
Here’s how Covid-19 has affected funding, development in infectious diseases
MedCity News
COVID-19
pandemic
infectious diseases
drug development
Flag link:
FDA Launches App for Reporting new Uses of Infectious Disease Drugs
FDA Launches App for Reporting new Uses of Infectious Disease Drugs
RAPS.org
FDA
infectious diseases
CURE ID
digital pharma
off-label
Flag link:
Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes
Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes
RAPS.org
FDA
JAMA
infectious diseases
drug development
surrogate endpoints
Flag link:
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More
Xconomy
Vir Biotechnology
IPOs
infectious diseases
Flag link:
Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs
Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs
Xconomy
Vir Biotechnology
IPOs
infectious diseases
Flag link:
Why Merck is in infectious disease for the long haul
Why Merck is in infectious disease for the long haul
BioCentury
Merck
R&D
infectious diseases
antibiotics
Flag link:
5 things to know about Hookipa Pharma ahead of its IPO
5 things to know about Hookipa Pharma ahead of its IPO
Marketwatch
Hookipa
IPOs
cancer
infectious diseases
Flag link:
Hookipa proposes IPO as its cancer vaccines head towards the clinic
Hookipa proposes IPO as its cancer vaccines head towards the clinic
BioCentury
Hookipa
IPOs
vaccines
cancer
infectious diseases
Flag link:
Researchers point to R&D treaty to spur new infectious disease treatments
Researchers point to R&D treaty to spur new infectious disease treatments
Endpoints
R&D
infectious diseases
Flag link:
ContraFect Corporation Prices $10 Million Public Offering of Common Stock to Develop Novel Infectious Disease Treatments
ContraFect Corporation Prices $10 Million Public Offering of Common Stock to Develop Novel Infectious Disease Treatments
CP Wire
ContraFect
infectious diseases
Flag link:

Pages